ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine

Department of Health

15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred to as Pfizer bivalent) for use as a booster COVID-19 vaccine in people aged 18 years and older. 

The Australian Technical Advisory Group on Immunisation has evaluated the immunogenicity, efficacy, and safety data on this vaccine.

Read Department of Health News

Michael Wonder

Posted by:

Michael Wonder